M. Friedman

发表

Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.

H. Brismar, G. Adams, J. Carlsson, 2007, Protein engineering, design & selection : PEDS.

Engineered affinity proteins for tumour‐targeting applications

S. Ståhl, M. Friedman, 2009, Biotechnology and applied biochemistry.

Affibody molecules targeting the epidermal growth factor receptor for tumor imaging applications

M. Friedman, 2008 .

Achieving directed immunostimulating complexes incorporation

S. Ståhl, M. Wikman, M. Friedman, 2006, Expert review of vaccines.

General strategies for efficient adjuvant incorporation of recombinant subunit immunogens.

S. Ståhl, M. Wikman, M. Friedman, 2005, Vaccine.

Protein tag-mediated conjugation of oligonucleotides to recombinant affinity binders for proximity ligation.

U. Landegren, A. Plückthun, Christian Jost, 2013, New biotechnology.

Elevated Serum GAD 65 and GAD 65-GADA Immune Complexes in Stiff Person Syndrome Gucci

Å. Lernmark, C. Hampe, C. Törn, 2015 .

Elevated Serum GAD65 and GAD65-GADA Immune Complexes in Stiff Person Syndrome

Å. Lernmark, U. Landegren, C. Hampe, 2015, Scientific Reports.

Affibody-mediated retention of the epidermal growth factor receptor in the secretory compartments leads to inhibition of phosphorylation in the kinase domain.

E. Lundberg, E. Vernet, P. Nygren, 2009, New biotechnology.

Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu

N. Habib, S. Ståhl, S. S. Hong, 2007, Cancer Gene Therapy.

Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.

E. Johansson, I. Höidén-Guthenberg, S. Ståhl, 2008, Journal of molecular biology.

Trailblazing Precision Medicine in Europe: a joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany.

S. Fröhling, L. Levin, D. Gisselsson, 2021, Seminars in cancer biology.

Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry

S. Ståhl, V. Tolmachev, F. Frejd, 2009, Journal of Nuclear Medicine.

Selection and characterization of an HIV‐1 gp120‐binding affibody ligand

S. Ståhl, P. Henning, L. Lindholm, 2006, Biotechnology and applied biochemistry.

Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber

S. Ståhl, P. Henning, L. Lindholm, 2009, Gene Therapy.

Engineering and characterization of a bispecific HER2 × EGFR‐binding affibody molecule

Fredrik Y Frejd, Helene Andersson-Svahn, Sara Lindström, 2009, Biotechnology and applied biochemistry.

Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2.

S. Ståhl, F. Frejd, L. Gedda, 2012, Bioconjugate chemistry.

Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule.

Hjalmar Brismar, Jörgen Carlsson, Bengt Glimelius, 2007, Nuclear medicine and biology.

Immunogenicity and protective effect against murine cerebral neosporosis of recombinant NcSRS2 in different iscom formulations.

S. Ståhl, J. Mattsson, M. Wikman, 2007, Vaccine.

Immunisation of mice against neosporosis with recombinant NcSRS2 iscoms.

S. Ståhl, J. Mattsson, M. Wikman, 2005, Veterinary parasitology.

In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells.

J. Carlsson, S. Ståhl, V. Tolmachev, 2008, Oncology reports.

Engineered affinity proteins for tumour‐targeting applications

S. Ståhl, M. Friedman, 2009, Biotechnology and applied biochemistry.